

Transcriptional Regulator Inhibitory Compounds (TRIC): Switches for Resistance, Virulence and Essential Genes

Marc Gitzinger¹, Birgit Schellhorn¹, Vincent Trebosc^{1,2}, Christian Kemmer¹, Peter Sennhen¹, Michel Pieren¹, Sergio Lociuro¹

¹ BioVersys AG, Hochbergerstrasse 60c, 4057 Basel, Switzerland ² Biozentrum, Klingelbergstrasse 50/70, 4056 Basel, Switzerland

The company

BioVersys is a privately-held Swiss biopharmaceutical company with major focus on the research and development of New Chemical Entities (NCEs) targeting Transcriptional Regulators.

By means of the company's award-winning, proprietary TRIC technology, BioVersys has shown that it is possible: A) to shut off resistance to a given antibiotic in XDR pathogens and therefore restore antibiotic efficacy, B) to tune down virulence factors and/or biofilm formation and thus reduce risks of infection (prophylaxis) or "boost" efficacy of available antibiotics and C) to prevent transcription of essential genes.

By this, BioVersys addresses high medical needs for new treatment options against life-threatening bacterial infections. In most cases, BioVersys' drug products will be used in combination with an existing antibiotic for instance to restore its efficacy against XDR pathogens; combination of an existing antibiotic with a TRIC-NCE represents an opportunity for rejuvenating IP of the "old" drug. The current research focuses on Nosocomial Infections (hospital infections) and Tuberculosis (TB). Against TB BioVersys is developing a TRIC candidate in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille.

